The landscape of recombinant therapeutic protein production is evolving rapidly. From single-chain proteins to complex bispecific formats, demand for high‑titer, high‑quality manufacturing has never been greater. While CHO‑based expression platforms remain the industry standard, can they keep pace with the changing needs of biologics production?
In this webinar, we’ll explore how innovations in DNA expression vector design are driving the next wave of productivity. Lonza will share insights into a high‑strength synthetic gene promoter that boosts titers while maintaining exceptional product quality and long‑term stability. You’ll discover how advances in GS® expression vector technology are enabling more efficient, reliable biomanufacturing across diverse therapeutic protein formats.
Join us to see how next‑generation expression vectors are shaping the future of protein therapeutics.
